CASC11 and prostate carcinoma: Besides, CASC11 may have the ability to become a potential diagnostic biomarker and a promising therapeutic target for CRC.79 Another typical clinical application example is lncRNA PCA3, which is highly expressed in prostate cancer, can be detected in urine samples of patients and has been demonstrated to have greater sensitivity and specificity for the early diagnosis of prostate cancer than the normally used prostate‐specific antigen (PSA) blood test.80